<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737707</url>
  </required_header>
  <id_info>
    <org_study_id>8108</org_study_id>
    <nct_id>NCT04737707</nct_id>
  </id_info>
  <brief_title>Dialectical Behavior Therapy for Adults With Autism Spectrum Disorders</brief_title>
  <acronym>Autisemo</acronym>
  <official_title>Dialectical Behavior Therapy for Adults With Autism Spectrum Disorders Without Intellectual Disability: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dialectical Behavior Therapy (DBT; Linehan, 1993) effectively diminishes emotion&#xD;
      dysregulation and self-harm behaviors in a number of disorders. However, to our knowledge, no&#xD;
      studies have investigated the efficacy of DBT to treat emotional dysregulation associated&#xD;
      with self-harm and suicidal behaviors in adults with ASD without intellectual disability.&#xD;
      This randomized controlled study trial aims to assess the efficacy of a 5-month DBT&#xD;
      intervention in adults with ASD without intellectual disability who present with self-harm&#xD;
      and/or suicidal behaviors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difficulties in Emotion Regulation Scale (DERS)</measure>
    <time_frame>baseline</time_frame>
    <description>The minimum value of the DERS scale is 0 and the maximum is 180. The higher the scores, the more severe the deregulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difficulties in Emotion Regulation Scale (DERS)</measure>
    <time_frame>at the end of therapy (5 months)</time_frame>
    <description>The minimum value of the DERS scale is 0 and the maximum is 180. The higher the scores, the more severe the deregulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difficulties in Emotion Regulation Scale (DERS)</measure>
    <time_frame>11 months follow-up</time_frame>
    <description>The minimum value of the DERS scale is 0 and the maximum is 180. The higher the scores, the more severe the deregulation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Dialectical Behavior Therapy (DBT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psychotherapy (duration 5 months) will begin within a maximum of 1 month (the time to set up the group) and will be accompanied by individual follow-up. Evaluations will be carried out within 6 months of the end of the psychotherapy in order to measure its effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>waiting list for 5 months before starting psychotherapy (duration 5 months). During this time, the patient can continue your usual therapeutic follow-ups. Likewise, assessments will be carried out within 6 months after the end of the psychotherapy in order to measure its effects. the patient will thus benefit from DBT regardless of the group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dialectical Behavior Therapy (DBT)</intervention_name>
    <description>Dialectical Behavior Therapy (DBT)</description>
    <arm_group_label>Dialectical Behavior Therapy (DBT)</arm_group_label>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  ASD diagnosis according to the DSM-5&#xD;
&#xD;
          -  IQ ≥ 70&#xD;
&#xD;
          -  Suicidal ideas, suicidal attempts and/or self-harm behaviors 6 months prior to the&#xD;
             inclusion&#xD;
&#xD;
          -  Able to understand and consent to the research aims&#xD;
&#xD;
          -  Membership in a health insurance fund&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  complete hospitalization&#xD;
&#xD;
          -  ongoing CBT or DBT&#xD;
&#xD;
          -  past DBT&#xD;
&#xD;
          -  schizophrenia disorders&#xD;
&#xD;
          -  under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luisa WEINER, MD</last_name>
    <phone>03 88 11 65 11</phone>
    <email>weiner.l@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Demonsant</last_name>
    <phone>03.88.11.67.68</phone>
    <email>eric.demonsant@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de psychiatrie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luisa Weiner</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

